Compare Neurocrine Biosciences Inc (NBIX) vs Williams Companies Inc (WMB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Neurocrine Biosciences Inc vs Williams Companies Inc — how do they compare? Neurocrine Biosciences Inc trades at $179 (market cap $17.40B), while Williams Companies Inc trades at $73.43 (market cap $90.70B). The key difference: Williams Companies Inc is far larger — about 5.2× Neurocrine Biosciences Inc's market cap, and Williams Companies Inc pays a 2.83% dividend while Neurocrine Biosciences Inc pays none. Which is the better fit depends on your goals.
| NBIX | WMB | |
|---|---|---|
Market Cap | $17.40B | $90.70B |
Sector | Health | Energy |
52-Week High | $180.55 | $79.40 |
52-Week Low | $123.10 | $56.51 |
Enterprise Value | $16.49B | $120.08B |
Dividend Yield | — | 2.83% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Neurocrine Biosciences (NBIX) trades at $173.00, up 1.24% today, with strong technical momentum and bullish moving averages. The company demonstrates robust fundamentals with Q1 2026 EPS of $1.94 beating expectations by 59%, revenue growth to $3.1B in 2026, and net income margin expanding to 21.55%. Recent news highlights executive appointments and positive clinical trial updates for crinecerfont, supporting growth prospects.
Outlook remains positive with 86% analyst buy ratings and a $196.08 consensus price target implying 13% upside. Key risks include execution of pipeline developments and integration of acquisitions. The stock's valuation at P/E 26.62 appears reasonable given earnings growth trajectory and strong profitability metrics.
Williams Companies (WMB) trades at $73.36, showing minimal daily movement with a slight 0.03% decline. The stock demonstrates strong profitability with 23.4% net income margins and 21.95% ROE, though valuation metrics appear elevated with a P/E of 32.53. Recent developments include a $5.34 billion Blackstone-led investment for power innovation projects and potential $5.5 billion Momentum Midstream acquisition, positioning the company for strategic growth in energy infrastructure.
WMB presents a compelling investment case with strong analyst support (79% buy ratings) and $86 consensus price target representing 17% upside. The company's fee-based midstream model provides revenue stability, while recent strategic investments enhance growth prospects. Key risks include commodity price volatility, execution challenges from major acquisitions, and elevated debt levels at 52% of assets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →About Williams Companies Inc
Williams is a midstream energy company that owns and operates the large Transco and Northwest pipeline systems and associated natural gas gathering, processing, and storage assets. In August 2018, the firm acquired the remaining 26% ownership of its limited partner, Williams Partners.
Read more on WMB →
